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Library preparation for whole-exome sequencing is a critical step serving the enrichment 
of the regions of interest. For Ion Proton, there are only two exome library preparation 
methods available, AmpliSeq and SureSelect. Although of major interest, a comparison 
of the two methods is hitherto missing in the literature. Here, we systematically evaluate 
the performance of AmpliSeq and SureSelect and present an improved variant calling 
pipeline. We used 12 in-house DNA samples with genome-wide and exome microarray 
data and a commercially available reference DNA (NA12878) for evaluation. Both methods 
had a high concordance (>97%) with microarray genotypes and, when validating against 
NA12878, a sensitivity and positive predictive values of >93% and >80%, respectively. 
Application of our variant calling pipeline decreased the number of false positive variants 
dramatically by 90% and resulted in positive predictive value of 97%. This improvement is 
highly relevant in research as well as clinical setting.
Keywords: exome sequencing, ion proton sequencer, AmpliSeq, SureSelect, library preparation, validation 
INTRODUCTION
Genome-wide association studies (GWAS) using microarray-based genotypes in large-scale 
epidemiological studies played an essential role in the dissection of complex traits (Kiezun et al., 
2012). With the evolution of next-generation sequencing (NGS), base-by-base characterization of the 
human genome became possible. The use of whole-genome sequencing is yet limited due to its high 
cost. Although whole-exome sequencing (WES) targets less than 2% of the genome (van Dijk et al., 
2014), it is a cost-effective way to detect both common and rare variants in protein-coding regions.
There are several NGS platforms available, but the largest share is of Illumina platforms followed 
by Ion Proton (Goodwin et al., 2016). The major steps in the NGS workflow are library preparation, 
sequencing, and data analysis. Library preparation is a critical step prior to enrichment, as it includes 
the targeted probe-based capture or amplification of target regions from genomic DNA. Most of the 
library preparation methods are designed for Illumina platforms, and several articles compared the 
performances of these methods (Clark et al., 2011; Lelieveld et al., 2015; Shigemizu et al., 2015). On 
the contrary, for Ion Proton, only two library preparation methods exist. These are AmpliSeq and 
SureSelect. Studies comparing these two WES library preparation methods are so far missing.
Previous studies have compared AmpliSeq on Ion platforms with various kits available for 
Illumina platforms for WES (Loman et al., 2012; Boland et al., 2013; Samorodnitsky et al., 2015). 
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They found that AmpliSeq on Ion platforms is a faster method 
with high throughput but faces problem in complex genomic 
regions. A recent in-detail evaluation of AmpliSeq WES using 
NA12878 reference calls (Damiati et al., 2016) highlighted the 
limitations of PCR-based target enrichment, provided the list 
of missed target regions and a filtering strategy to reduce the 
number of false positives (FPs).
Studies comparing the only two library preparation methods, 
namely, AmpliSeq and SureSelect for Ion Proton, are, however, 
so far missing. The aims of our study were 1) to compare the 
performance of AmpliSeq and SureSelect and 2) to develop an 
optimized protocol for variant calling for WES on Ion Proton 
platform. We calculated concordance rates between variants 
detected by sequencing and genome-wide and exome chip 
genotyping data from 12 in-house DNA samples and validated 
our sequencing protocol against the well-characterized NA12878 
reference DNA v3.3.2 by documenting sensitivity and positive 
predictive value (PPV) at each optimization step (Zook et al., 
2014; Zook et al., 2016) (Figure 1).
To our knowledge, this is the first study systematically 
comparing the performances of AmpliSeq and SureSelect on Ion 
Proton. We also extend previous findings on the validity of Ion 
Proton sequencing using AmpliSeq by evaluating different target 
regions, coverage ranges (44x to 270x) using wet lab sequencing 
and by manually inspecting all false negative (FN) and FP 
variants on chromosome (Chr) 1,7,16,19, and X and categorizing 
them based on their possible causes.
Importantly, AmpliSeq and SureSelect are library preparation 
and enrichment protocols, which might be chosen prior to 
sequencing technologies (Illumina vs. Ion Proton). The nature 
of the sequencing step is, therefore, the object of interrogation. 
In our study, we aimed to address Ion Proton users and provide 
a useful point of reference for those who wish to pursue exome 
sequencing on Ion Proton platform.
MATERIALS AND METHODS
DNA
We used 12 in-house DNA samples previously genotyped by 
Affymetrix Genome-Wide Human SNP Array 6.0 (n = 11) or 
Human610-Quad BeadChip (n = 1) (Thermo Fisher Scientific, 
USA) and by Exome chip Illumina Infinium Exome-24 v1.1 
BeadChip array (n = 12) (Illumina Inc., USA). We used the raw 
data from microarray without any filtration such as minor allele 
frequency. Altogether six samples (female: 1, males: 5, mean 
age: 55.7) were withdrawn from the Austrian Stroke Prevention 
Study (Schmidt et al., 1994), a longitudinal community-
dwelling cohort study on brain aging in the city of Graz, Austria. 
The remaining six samples (females: 2, males: 4, mean age: 
74.3) were part of the Prospective Registry on Dementia in 
Austria (Seiler et al., 2012) and represented patients clinically 
diagnosed with probable Alzheimer’s dementia. Reference 
DNA NA12878 (Reference Material 8398) (Zook et al., 2014) 
was obtained from the “National Institute of Standards and 
Technology.” In-house DNA samples were extracted from whole 
peripheral ethylenediaminetetraacetic acid blood using the 
phenol–chloroform method and stored at -80°C. All DNAs were 
checked on 1.5% agarose gel and quantified using NanoDrop 
3300 fluorospectrometer (Thermo Fisher Scientific, USA) 
before sequencing.
Library Preparation and Sequencing
Ion AmpliSeq Exome
Library preparation was done with the Ion AmpliSeq™ library kit 
plus (Life Technologies, USA) using 100 ng of DNA (100 ng/µl) 
according to the manufacturer’s protocol. Briefly, after amplifying 
the target region using 12 pools of Ion AmpliSeq™ primers 
(24,000 primer pairs totaling to 294,000), we partially digested 
the primer sequences and ligated adapters and barcodes to the 
amplicons. Using the AMPure XP reagent purification system 
(Beckman Coulter Life Sciences, USA), 50 µl of the purified 
unamplified library was retrieved. We used Ion AmpliSeq™ 
Exome RDY plate to amplify eight different and barcoded 
genomic DNAs at the same time.
SureSelect All Human Exome V6
We prepared the library using the SureSelect Target 
Enrichment System (Agilent Technologies, USA) following 
the manufacturer’s protocol. After fragmenting 1µg of genomic 
DNA (100 ng/µl) using Ion Shear Plus Reagents for enzymatic 
fragmentation, we purified and size-selected the library using 
FIGURE 1 | Workflow of the study design. The same color represents the 
steps at the same level. Identical steps are used to analyze both methods. 
AS, AmpliSeq; SS, SureSelect; TTR, Total Target Region; ETR, Effective 
Target Region; OTR, Overlapping Target Region; TPs,True Positives; FNs, 
False Negatives; FPs, False Positives; PPV, Positive Predictive Value.
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AMPure XP beads (Beckman Coulter Life Sciences, USA). We 
ligated Ion Xpress barcodes and P1 adapters to the end of DNA 
fragments and then amplified the library. Next, the amplified 
DNA fragments were hybridized to biotinylated RNA library 
baits and captured using streptavidin-coated magnetic beads. 
Finally, captured library fragments were amplified and quality 
assessed on 2100 Bioanalyser (Agilent Technologies, USA).
We used Ion library TaqMan™ quantitation kit (Life 
Technologies, USA) on the 7900 real-time PCR system (Applied 
Biosystems, USA) for quantitation of both unamplified libraries. 
We did template preparation using Ion PI™ Hi-Q™ chemistry 
(Life Technologies, USA). We loaded 50 pM of each library on 
Ion Chef ™ Instrument (Life Technologies, USA) for template 
enrichment. We performed quality control to assess templating 
efficiency of Ion spheres using Qubit™ 2.0 Fluorometer (Thermo 
Fischer Scientific, USA). We loaded prepared libraries onto 
Proton PI chips v3 (two samples/chip for in-house DNAs; one 
sample/chip for reference DNA) and sequenced them on Ion 
Proton using PI™ Hi-Q™ sequencing 200 chemistry (Life 
Technologies, USA) aiming for read length of 260 bp and 520 
flow cycles.
Data Analysis
We used Ion Torrent Suite1 version 5.4 (Life Technologies, USA) to 
analyze the data. We used Torrent Mapping Alignment Program 
version 5.2 for alignment against human hg19 assembly and 
Torrent Variant Caller (TVC) version 5.4 under the default low 
stringency settings to call variants. We analyzed the variants in 
the library-specific total target region (TTR). Also, for AmpliSeq, 
we used the effective target region (ETR) (Supplementary 
Datasheet 2), which is introduced by the manufacturer in the 
default Ion Torrent pipeline to exclude poor performing regions 
enriched for FPs or having low coverage. We downloaded the 
RefSeq-, Ensembl-, and University of California—Santa Cruz 
(UCSC)-defined coding regions from UCSC genome browser in 
the form of BED files (20/04/2017).
We used v3.3.2 of high-confidence calls vcf file of NA12878 
from Genome in the Bottle project (Zook et al., 2014) downloaded 
from their ftp server for validation of our data. For optimizing our 
pipeline, we used the high-confidence region (HCR), provided as 
BED file (Zook et al., 2014; Zook et al., 2016). HCR specifies those 
regions in the genome where genotypes can be called confidently. 
These regions were generated after arbitrating between 11 whole-
genome and 3 exome data sets from 5 sequencing platforms and 
7 mappers by Zook et al. (2014) and carefully filtering uncertain 
sites. These regions were provided as BED file. We intersected the 
target regions from AmpliSeq and SureSelect with the provided 
HCR to get the HCRs in the respective target design.
We used bedtools (Quinlan and Hall, 2012) to manipulate 
BED files and vcf files and bcftools2 to calculate the true positives 
(TPs), FNs, and FPs. We used vcflib3 vcfallelicprimitives module 
to generate phased genotypes and vt to regularize the variants 
1Ion Torrent Suite Software 5.4 https://assets.thermofisher.com/TFS-Assets/LSG/
manuals/MAN0016409_TorrentSuite5_4Help pdf.
2Samtools/bcftools. GitHub. https://github.com/samtools/bcftools
3vcflib/vcflib. GitHub. https://github.com/vcflib/vcflib
(Tan  et al., 2015). The vcfallelicprimitive module splits the 
multiple representations of a single record in a vcf file into 
multiple lines. This is necessary as indels and complex variants 
are frequently called differently depending upon the aligner 
used to create BAM files. It results in the representation of 
multi-nucleotide variants as two SNVs. The vt tool performs 
normalization by left alignment and presents a variant in as few 
nucleotides as possible. The normalization helps to compare the 
variants called by the different variant caller to minimize errors.
For in silico downsampling, we used samtools view -s option 
that selects the desired number of reads from a big BAM file 
(Li et  al., 2009). We used the tools picard4, samtools, and a 
java-based tool “MarkDupbyStartEnd”5 to remove duplicates. 
We applied different combinations of parameters for variant 
calling on TVC to get a balance between FNs and FPs. Finally, 
we visualized all FNs and FPs on Chr 1, 7, 16, 19, and X using 
Integrative Genomics Viewer (IGV) (Robinson et al., 2011). We 
used Rstudio for statistical computation and graphics6.
Categorization of False Negatives and 
False Positives
We manually inspected all FNs and FPs on Chr 1, 7, 16, 19, and 
X. We selected Chr 1, as it is the largest chromosome and has 
the highest number of FNs, Chr 7 and 16 as they have a high 
density of exonic monomer repeats, Chr 19 as it has the highest 
density of sequence repeats, and Chr X as representation of 
a sex chromosome (Subramanian et al., 2003). We classified 
FNs due to possible causes related to 1) library-derived issues 
such as coverage, genotype, and read quality or a combination 
of these and 2) sequencer-derived issues such as location in 
a homopolymer region and signal shifts or both. When we 
cannot identify the reason behind an FN, we categorized it as 
unknown. We classified FPs into six categories by inspecting 
each position on IGV. 1) Strand bias: ≤2% of reads of alternate 
alleles are from one strand, 2)  Read end: a variant present 
within five nucleotides at the end of a read, 3) Low quality: the 
quality of the variant call was less than 20, 4) Homopolymer: 
a variant inside or next to a repeat stretch of four or more 
nucleotides, 5) Mixed allele: more than one alternate allele 
was present at that particular position, 6) Unknown: variants 
failed to be categorized under the mentioned five categories.
Z Score for Coverage Comparison and 
Evenness of Coverage
We divided read depth into 45 categories. For the lower end of 
read distribution (0X–10X), we used an increment of 5X, through 
10X–400X an increment of 10X, and above 400X that of 200X. 
This allowed us a high-resolution comparison of the distribution 
of reads in the low read depth region (<10X) and in the callable 
region. The callable range is defined between 5X and 400X and 
4Picard http://broadinstitute.github.io/picard
5MarkDupsByStartEnd Github. https://github.com/dariober/Java-cafe/tree/
master/MarkDupsByStartEnd
6RStudio Team. RStudio: Integrated Development for R. RStudio, Inc., Boston, 
MA http://www.rstudio.com/
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was set by the manufacturer in order to reduce the computation 
time. Next, we calculated the difference in the coverage between 
the AmpliSeq and SureSelect for each category. We computed 
the normalized difference in coverage as follows:
Diffcoverage = AmpliSeqcoverage - SureSelectcoverage
Z = (Diffcoverage- Mean(Diffcoverage)/SD(Diffcoverage)
Where SD(Diffcoverage) is the standard deviation of the 
difference in coverage.
Z > 0 means higher AmpliSeq coverage than SureSelect and 
vice versa.
We calculated the evenness of coverage for both libraries to 
compare the target enrichment by dividing the per base coverage 
by the average depth.
RESULTS
Comparison of AmpliSeq and SureSelect 
Laboratory Protocol and Design
A detailed description of the design and protocol is presented in 
Table 1. Briefly, by design, AmpliSeq TTR targets 57,742,646 bp 
and SureSelect TTR 60,456,963 bp. The overlapping target region 
(OTR) is 43,173,762 bp. AmpliSeq TTR covers 91.1, 88.6, and 
87.9% while SureSelect TTR 87.9, 87.8, and 87.4%, of RefSeq-, 
Ensembl-, and UCSC-defined coding regions, respectively. The 
size of AmpliSeq ETR is 46,347,343 bp and covers 86.3, 83.7, and 
83.1% of the RefSeq-, Ensemble-, and UCSC-coding regions. 
We found that in both the libraries, the missed regions were 
exclusively located in the coding region. AmpliSeq by design 
missed 3,016,767, while SureSelect missed 4,227,905 bases from 
RefSeq-coding regions.
Analysis of In-House DNA Samples
The mean number of reads was 34.2 million for AmpliSeq and 39.8 
million for SureSelect. The mean read depth values were 92X for 
AmpliSeq and 69X for SureSelect. Out of the total number of reads 
produced by each method, 94% in AmpliSeq and 86% in SureSelect 
were mapped to their respective target regions, a difference that 
was statistically significant (p < 0.0001). The percentage of bases 
covered >50X and >5X were 63 and 97.3% with AmpliSeq and 
50.3 and 97.9% with SureSelect (Supplementary Table 1). Under 
the default low-stringency settings of TVC, the mean numbers 
of variants including singletons over all samples were 51,413 in 
AmpliSeq and 51,783 in SureSelect TTR (Supplementary Table 2). 
The mean concordance rates were around 98% with exome chip 
and 99.5% with the GWAS chip genotypes for both libraries 
(Supplementary Table 3). We disregarded homozygous reference 
calls. Concordance rates were somewhat lower (AmpliSeq: 95%, 
SureSelect: 92%) for rare variants (MAF < 0.05%).
Analysis of NA12878 Reference DNA 
Coverage
The average depths of coverage were 270X for AmpliSeq 
and 115X for SureSelect. The proportions of bases covered 
between 5X and 400X were 79.4% for AmpliSeq and 98.5% for 
SureSelect, covered >400X was profoundly larger for AmpliSeq 
(19.9%) than for SureSelect (0.9%) and covered less than 5X 
was similarly low for both (<1%) (Supplementary Table 4). 
Both libraries covered approximately 40% of the total targeted 
bases with more than the average depth, however, in AmpliSeq 
percentage of bases covered less than 10X was higher than that 
in SureSelect (Figure 2).
Variant Detection
By using AmpliSeq, we identified 54,351 variants, while by 
using SureSelect, the number of detected variants was 54,934 
(VCF1). The overall sensitivity and PPV were 93.1 and 84.5% 
for AmpliSeq and 93.5 and 80% for SureSelect, respectively. 
The sensitivity and PPV for detecting SNVs were higher than 
those for detecting indels by using both libraries (Table 2). 
Performing variant calling on 34 million randomly selected 
reads from both libraries to reduce the coverage bias resulted 
in 53,068 and 52,918 variants within AmpliSeq and SureSelect 
TTRs. AmpliSeq had a sensitivity of 91.8% and PPV of 85.3%, 
TABLE 1 | Comparison of laboratory protocols and design of AmpliSeq and SureSelect library preparation methods.
  AmpliSeq SureSelect
P
ro
to
co
l
Enrichment approach PCR Hybridization
DNA input 100 ng 1 µg 
Steps in library preparation 3 8
DNA fragmentation NA Enzymatic fragmentation
 Target selection Amplification using primers Hybridization with RNA library baits 
 Incubation time ~4 h ~26 h
Library Preparation time 6 h 2.5 days
Ta
rg
et
 R
eg
io
n
Total target region 57.74 MB 60.45 MB
 RefSeq coding 32.30 MB (91.13%) 31.15 MB (87.88%)
 UCSC coding 32.57 MB (88.65%) 32.26 MB (87.78%)
 Ensembl coding 32.40 MB (87.90%) 32.23 MB (87.44%)
Effective target region 46.35 MB NA
 RefSeq coding 30.58 MB (86.28%) NA
 UCSC coding 30.76 MB (83.72%) NA
 Ensembl coding 30.62 MB (83.07%) NA
NA, not applicable; MB, million bases.
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whereas SureSelect had a sensitivity of 91% and PPV of 80.8% 
(Supplementary Table 5).
Optimization-Variant Calling Pipeline
Upon regularization, as recommended by Zook et al., 2014, the 
number of TPs increased by 714 to 46,660 using AmpliSeq and 
by 622 to 44,551 using SureSelect (VCF2). At the same time, FPs 
increased by 176 to 8,581 and by 275 to 11,280, respectively. By 
using the HCR BED file to exclude difficult-to-sequence regions, 
the number of FPs decreased significantly from 8,581 to 1,218 in 
AmpliSeq and from 11,005 to 947 in SureSelect, while the number 
of TPs decreased minimally by 0.7% (VCF3) (Table  3). The 
sensitivity and PPV for detection of SNVs were 98.7 and 98.3% 
for AmpliSeq and 98.8 and 98.6% for SureSelect, respectively. 
Corresponding values for indels were 52.7 and 82.7% for AmpliSeq 
and 49.1 and 84.4% for SureSelect, respectively (Figure 3).
The total number of TP, FN, and FP indels were 2,121, 1,904, and 
445 by AmpliSeq and 1,710, 1,771, and 335 in SureSelect, respectively. 
The overlapping positions of TP, FN, and FP indels were 870, 642, and 
31 between the two libraries, respectively (Supplementary Tables 6 
and 7). Out of 1,261 indels missed by AmpliSeq, 132 were detected 
by SureSelect, while out of 1,128 indels missed by SureSelect, 247 
were detected by AmpliSeq (Supplementary Figure 1).
Last, we repeated variant calling by changing the default 
parameter settings in a stepwise manner while keeping HCR as 
a target region for each library. While SureSelect had the best 
performance with the default parameter settings, AmpliSeq 
performed best when the parameter “minimum allele frequency” 
FIGURE 2 | Evenness of coverage, per base depth of coverage and its comparison between AmpliSeq and SureSelect methods. (A) Evenness of coverage plotted 
for original and downsampled BAM files (B) Scatter plot showing the distribution of per base coverage of AmpliSeq and SureSelect till 1000X read depth. (C) A bar 
chart is showing the difference in coverage after dividing the depth of coverage into 45 groups and normalization. SureSelect covers more bases in the coverage 
range of 11X to 150X than AmpliSeq. AS, AmpliSeq; SS, SureSelect.
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was changed to 0.2 (step 2). In AmpliSeq, PPV improved 
from 97.4 to 98.1% with a reduction of sensitivity by 0.3% 
(Supplementary Table 8 and Supplementary Figure 2). To 
equalize read depth over two methods, we downsampled both 
libraries to 34 million reads as well as to an average depth of 100X 
and observed a similar increase in PPV to 98% and a minimum 
reduction in sensitivity (Supplementary Table 5).
AmpliSeq Effective Target Region
In ETR, AmpliSeq detected a total of 38,651 variants with 33,119 
being TPs, 1,251 FNs, and 5,532 FPs. Using regularization and 
restricting the analysis to HCR resulted in a substantial reduction 
of FPs by 91% and increased PPV to 98.5% while maintaining 
sensitivity at 98% (Supplementary Table 9).
Variant Detection in RefSeq Coding 
Region and Overlapping Target Region
In the RefSeq-coding region, we detected 17,836 variants using 
AmpliSeq and 17,312 using SureSelect out of the expected 19,270 
coding variants present in NA12878 truth set. After regularization 
and using HCR, sensitivity increased slightly from 92.6 to 93.4% 
for AmpliSeq and from 89.8 to 90.5% for SureSelect, whereas 
PPV increased considerably from 82.6 to 98.1% and 80 to 98.1%, 
respectively (Table 4).
Next, we compared the performances of both libraries in 
the OTR of 43.2 million base pairs at the same average depth 
of 115X. After regularization and restricting analyses to HCR, 
we saw a similar improvement as that of TTR or RefSeq-
coding region. The sensitivity of both methods was around 
95%, and PPV was improved from 85 to 98% (Table  4). In 
OTR, out of the total TPs called by each method, 30,266 
were shared, leaving 1–2% of variants specific to each library 
(Supplementary Figure 3).
De-Duplication
Removing duplicates using picard and samtools resulted in 
an 88% loss of reads in AmpliSeq and 30% loss in SureSelect. 
Therefore, we did not perform variant calling in AmpliSeq. Using 
the tool “MarkDupbyStartEnd,” the loss was 13% in AmpliSeq 
and 0.1% in SureSelect. There was no change in the performance 
of either library by applying de-duplication strategies, and 
sensitivity remained around 94% and PPV 98% for both libraries 
(Supplementary Table 10).
Exploration of False Negatives and False 
Positives
Manual inspection of all FNs on Chr 1, 7, 16, 19, and X 
(Supplementary Figure 4) showed that the FN SNVs were 
mainly due to library-derived issues (74–95%) whereas indels 
TABLE 3 | Variant validation in various steps of optimization using NA12878 truth set.
Steps Total Variants Truth set TPs FNs FPs Sensitivity PPV
AmpliSeq
TTR (VCF1) 54,351 49,340 45,946 3,394 8,405 93.12% 84.54%
RG (VCF2) 55,241 49,340 46,660 2,680 8,581 94.57% 84.47%
HCR (VCF3) 47,538 48,796 46,320 2,476 1,218 94.93% 97.44%
SureSelect
TTR (VCF1) 54,934 46,982 43,929 3,053 11,005 93.50% 79.97%
RG (VCF2) 55,831 46,982 44,551 2,431 11,280 94.83% 79.80%
HCR (VCF3) 45,200 46,557 44,253 2,304 947 95.05% 97.91%
Truth set—Variants in v3.3.2 of high-confidence calls VCF of NA12878 from Genome in the Bottle project, TPs, True Positives; FNs, False Negatives; FPs, False Positives; PPV, Positive 
Predictive Value, VCF1–3—This corresponds to Figure 1, TTR, Total Target Region; RG, Regularization; HCR, High-Confidence Region. 
TABLE 2 | Variant validation of default TVC output (VCF1) against NA12878 truth set.
 Total Variants Truth set TPs FNs FPs Sensitivity PPV
AmpliSeq
Total Variants 54,351 49,340 45,946 3,394 8,405 93.12% 84.54%
Total SNVs 50,913 45,092 43,840 1,252 7,073 97.22% 86.11%
Exonic SNVs 19,650 16,964 16,588 376 3,062 97.78% 84.42%
Total Indels 3,436 4,248 2,106 2,142 1,330 49.58% 61.29%
Exonic indels 539 329 231 98 308 70.21% 42.86%
SureSelect
Total Variants 54,934 46,982 43,929 3,053 11,005 93.50% 79.97%
Total SNVs 52,013 43,367 42,230 1,137 9,783 97.38% 81.19%
Exonic SNVs 19,171 16,120 15,846 274 3,325 98.30% 82.66%
Total Indels 2,921 3,614 1,699 1,915 1,222 47.01% 58.17%
Exonic indels 312 277 195 82 117 70.40% 62.50%
Truth set—Variants in v3.3.2 of high-confidence calls VCF of NA12878 from Genome in the Bottle project, SNVs,Single Nucleotide Variants; TPs,True Positives; FNs, False 
Negatives; FPs, False Positives; PPV, Positive Predictive Value; TVC, Torrent Variant Caller, VCF1—This corresponds to Figure 1.
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were due to all three, namely library derived, sequencer derived 
or both issues (14–58%) in both libraries (Supplementary 
Tables 11–17). We validated our classification of FNs by 
scrutinizing shared FN positions between the two methods (Chr 
1: 35 and Chr X: 18) and found that, except for two positions, 
the classification was concordant. Among the clearly classifiable 
FP SNVs (Supplementary Figure 5), strand bias was the major 
cause in AmpliSeq (51–61%), while in SureSelect, homopolymers 
played a prominent role (18-50). Homopolymer-related 
issues explained most FP indels (44–79%) in both methods 
(Supplementary  Tables 18–24). We did not find any major 
differences between the causes of FNs or FPs in the respective 
TTRs or library-specific regions in either library.
Effect of Increasing Average Read Depth 
on AmpliSeq Performance
Increasing average depth from 44X to 270X had a significant 
effect on the per base coverage (Supplementary Figure 6). 
Importantly, raising average read depth led to decrease in 
bases covered <5X (3,188,163 to 400,116) but, on the same 
time also, to a disproportional increase in the number of bases 
covered >400X (19,602 to 11,494,834). This resulted in a relevant 
decrease in the number of bases in the callable range (5X–400X 
from 55,687,667 at 44X to 45,880,764 at 270X). Sensitivity 
increased significantly from 86.2 to 94.9%, while the change in 
PPV was negligible (96.9 to 97.4%) (Supplementary Table 25).
DISCUSSION
In the present study, we compared the performance of the 
AmpliSeq and the SureSelect library preparation methods, the 
two presently available methods for WES on the Ion Proton 
platform. By design, AmpliSeq covers a slightly larger proportion 
of the RefSeq-, Ensembl-, and UCSC-coding regions than does 
SureSelect. When comparing with exome chip genotype data, 
both show excellent concordance rates of 97%. Validating the 
two methods against NA12878 truth set revealed a comparable 
sensitivity (93%) but a higher PPV for AmpliSeq (84.5%) than 
for SureSelect (80%). By applying regularization using HCR 
and altering the default parameter settings for variant calling, 
we were able to reduce the number of FPs by approximately 
90% and reach a final sensitivity of 95% and PPV of 97% for 
both methods.
TABLE 4 | Comparing performance of AmpliSeq vs. SureSelect within RefSeq-coding region and overlapping target region.
R
ef
S
eq
-c
o
d
in
g
 r
eg
io
n
Steps Total Variants Truth set TPs FNs FPs Sensitivity PPV
AmpliSeq
TTR (VCF1) 21,584 19,270 17,836 1,434 3,748 92.56% 82.64%
RG (VCF2) 21,878 19,270 18,087 1,183 3,791 93.86% 82.67%
HCR (VCF3) 18,331 19,270 18,009 1,261 322 93.46% 98.24%
SureSelect
TTR (VCF1) 21,649 19,270 17,312 1,958 4,337 89.84% 79.97%
RG (VCF2) 21,943 19,270 17,523 1,747 4,420 90.93% 79.86%
HCR (VCF3) 17,747 19,270 17,443 1,827 304 90.52% 98.29%
O
T
R
 1
15
X
AmpliSeq
TTR (VCF1) 35,093 32,213 30,367 1,846 4,723 94.27% 86.53%
RG (VCF2) 35,550 32,213 30,788 1,425 4,762 95.58% 86.60%
HCR (VCF3) 31,161 31,979 30,611 1,368 550 95.72% 98.23%
SureSelect
TTR (VCF1) 36,228 32,213 30,651 1,562 5,577 95.15% 84.61%
RG (VCF2) 36,744 32,213 31,067 1,146 5,677 96.44% 84.55%
HCR,(VCF3) 31,478 31,979 30,896 1,083 582 96.61% 98.15%
Overlapping target region (OTR) —this is the common region covered by both AS and SS designs. This region is 43.17 Mb, RefSeq-coding region—this is the coding region from 
RefSeq database, downloaded from UCSC table browser on 20/04/2017. NA12878 truth set has 19,270 variants, Truth set—Variants in v3.3.2 of high-confidence calls VCF 
of NA12878 from Genome in the Bottle project, SNVs, Single Nucleotide Variants; TPs, True Positives; FNs, False Negatives; FPs, False Positives; PP, Positive Predictive Value, 
VCF1–3—This corresponds to Figure 1, RG, Regularization; HCR, High-Confidence Region.
FIGURE 3 | Effect on optimization-variant calling pipeline. Effect of 
optimization steps shown on total variants, true positives, false positives, 
sensitivity, and PPV in AmpliSeq and SureSelect. Blue represents AmpliSeq 
and red SureSelect. PPV, positive predictive value.
Exome Sequencing on Ion ProtonGampawar et al.
8 September 2019 | Volume 10 | Article 856Frontiers in Genetics | www.frontiersin.org
Protocol and Design
Owing to its PCR-based design, the laboratory protocol of 
the AmpliSeq method is considerably faster (6 h), consists 
of fewer preparation steps, and requires less hands-on time 
than SureSelect. Starting from genomic DNA, it allows the 
identification of exonic variants within 48 h. The low amount of 
input material required is a further advantage over SureSelect. 
Therefore, when the amount of starting material is low and time 
is a constraint, AmpliSeq is the method of choice.
Microarray Concordance
Both methods have similarly excellent concordance rates 
of >97% against exome chip and >99% against GWAS chip 
genotype data. The comparable concordance rates despite the 
lower average read depth in SureSelect is probably due to a more 
favorable distribution of the per-base coverage. As we describe 
in the NA12878 sequencing results, the proportion of bases in 
the callable range (5-400x) was significantly higher in SureSelect 
(98.49%) than in AmpliSeq (79.49%). The callable range was set up 
by the manufacturer to reduce the computation time. Moreover, 
in case of very rare variants (MAF < 0.05%) sequencing detected 
on average 90% more variants than the exome chip.
Variant Detection
Validating sequencing data against microarrays has been 
shown to overestimate sensitivity and is prone to errors at 
indels and phased genotypes (Zook et al., 2014). Therefore, 
as recommended (Zook et al., 2014), we also used high-
confidence genotypes from the NA12878 truth set to validate 
the two libraries and found that sensitivity was comparable 
for both methods (93.1 vs. 93.5%) while PPV was relevantly 
higher for AmpliSeq (84.5 vs. 80%).
Optimization-Variant Calling Pipeline
In order to improve the validity of variant calling, we used 
1)  regularization, 2) restriction to HCR, and 3) changing 
default parameter settings. The regularization had the strongest 
effect on the reduction of FNs by 20% in both libraries. This was 
due to breaking down complex variants to their simplest form, 
generating phased genotypes. The most remarkable reduction in 
FPs (AmpliSeq by 85.8%, SureSelect by 91.6%) could be achieved 
by restricting the analyses to the HCR. This effect is due to the 
exclusion of complex, difficult to sequence areas such as simple 
repeats, tandem duplications, regions inside structural variants, 
etc. of the genome (Zook et al., 2014). Recently, Samorodnitsky 
et al. (2015) also reported that PCR-based methods are more 
prone to errors in complex genomic regions. However, using 
HCR reduces the target coding region by 5.5 MB in AmpliSeq 
and 6.8 MB in SureSelect with important implications for 
the identification of pathogenic variants in rare diseases. We, 
therefore, provide a list of regions excluded while using HCR 
(Supplementary file). If pathogenic variants are expected in 
these regions, we recommend variant calling against the TTR 
using a list of all known pathogenic variants (hotspot list). This 
strategy delivers genotypes at all positions given on the hotspot 
list even when the individual is homozygous for the reference 
allele.
Fine-tuning by changing parameter settings for variant calling 
reduced FPs significantly by 27% only in AmpliSeq but had 
practically no effect in SureSelect (Supplementary Table  26). 
This difference is probably due to the fact that in SureSelect, 
strand bias and minimal allele frequency, which are influenced 
by PCR, are of less concern.
We found that for the detection of SNVs, both AmpliSeq and 
SureSelect have high sensitivity and PPV; however, for detecting 
indels, sensitivity and PPV are significantly reduced for both 
methods. Our estimates for the performance of the AmpliSeq 
method are in line with the previous study (Damiati et al., 2016); 
however, for comparing our results on SureSelect performance 
on Ion Proton, no study is available so far.
AmpliSeq Effective Target Region
When using our optimization pipeline with ETR instead of 
TTR, the number of FPs and FNs was substantially reduced, 
resulting in a relevant improvement in PPV from 85.7 to 98.5%. 
A drawback of using ETR was, however, the significant reduction 
of TPs by 28%. This is an important novel finding, as the use 
of ETR by default is recommended by the manufacturer. We, 
however, strongly recommend using our pipeline together with 
TTR instead of ETR.
RefSeq-Coding Region and Overlapping  
Target Region
Focusing on the RefSeq-coding region and OTR, we could achieve 
a more valid comparison of two methods. In the RefSeq-coding 
region, AmpliSeq detected 3% more variants than SureSelect. 
This was probably due to the fact that AmpliSeq by design covers 
3.2% more of the RefSeq-coding region than SureSelect does. In 
OTR, the performances of both methods were identical.
Importantly, our data show that it is possible to combine the 
genotypes from both methods for meta-analysis, as we found 
that within OTR; ~98% TP variants were shared by both libraries, 
and the number of library-specific variants were reduced to 
a minimum.
De-Duplication
As AmpliSeq is a PCR-based library preparation method, PCR 
duplicates removal using standard practices resulted in the loss 
of most reads (88%), whereas, in SureSelect, it did not improve 
the outcome. Moreover, as suggested by Ebbert et al. (2016), 
duplicate removal had a minimal effect on downstream variant 
calling. Therefore, we do not suggest duplicate removal on either 
of the libraries on Ion Proton.
Exploration of False Negatives and  
False Positives
Irrespective of the library used, library-related issues dominated 
FN SNVs, whereas, for FN indels, library as well as sequencer-
related problems contributed evenly. FP SNVs in AmpliSeq were 
predominantly due to strand bias, a PCR-related issue; hence, 
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increasing the parameter “minimum allele frequency” led to a 
significant reduction of FPs by 27%. Homopolymers were the 
major cause of FP indels in both methods. Therefore, regardless 
of the chemistry used for library preparation, FN and FP indels 
on Ion Proton were mainly due to the sequencing technology. 
This is in line with previous findings showing a high rate of 
errors in complex genomic regions using Torrent technology 
(Samorodnitsky et al., 2015). FPs categorized as “unknown” were 
located mainly in complex regions.
Many of these FN and FP variants could be overcome by 
the use of third-generation sequencing, as these techniques 
lack amplification steps and therefore hinders introduction of 
chimeric reads, variation in repeat size, and under-representation 
of GC-rich/poor regions (Ardui et al., 2018), hence, allow an 
accurate detection of variants in difficult-to-sequence regions. 
Especially, as reported by Huddleston et al. (2017), by using third-
generation sequencing, a significant improvement in detecting 
indels >7 bp and structural variants <1 kilobase, which account 
for the majority of differences between genomes, is expected.
Effect of Coverage on AmpliSeq 
Performance
Contrary to our expectations, increasing the mean read depth 
from 44X to 270X did not result in a reduction of FNs and FPs. 
Rather, we observed that the performance was reaching a plateau 
between 80-90X. Indeed, an increase in average read depth 
exponentially increased the number of bases covered >400X 
but not those covered <5X (Supplementary Table  25). This is 
most probably due to PCR-based biases that occur during the 
target selection and library enrichment. These results echoed 
the previous finding using in silico downsampling (Damiati 
et  al., 2016). Those regions covered by AmpliSeq with less 
than 5X, SureSelect design targeted 62%. Out of these 62% 
targeted regions, 72% were covered by ≥5X by SureSelect 
(Supplementary Figure 7).
Mapping and Variant Calling Pipelines
As most of the Proton users apply the user-friendly Torrent 
Mapping Alignment Program + TVC pipeline provided by the 
manufacturer, we aimed to evaluate the two library preparation 
methods using this pipeline. Torrent Suite is optimized for Ion 
Torrent data and is constantly updated, resolving the weaknesses 
associated in each version. We did not test alternative variant 
calling pipelines because previous reports clearly showed that for 
the analysis of data from Ion Torrent platforms, Torrent Suite is 
the most sensitive and specific (Caboche et al., 2014; Vanni et al., 
2015; De Summa et al., 2017).
Strengths and Weaknesses
The strength of our study lies in the stepwise and thorough 
comparison of the AmpliSeq and SureSelect methods, including 
their design, protocols, sequencing performances, and variant 
calling. We performed 24 sequencing experiments on in-house 
DNAs with GWAS and exome chip genotype data, and six 
sequencing runs on the reference NA12878 DNA. We estimated 
the validity of the methods by calculating the concordance rates 
against microarray genotypes as well as the number of TPs, FNs, 
FPs, sensitivity, and PPV using high-confidence genotypes from 
NA12878. We optimized the variant calling pipeline by using 
regularization, HCR, and alternative parameter settings. This 
finally led to a substantial improvement in sensitivity and PPV 
for both methods. We manually inspected all FNs and FPs on 
Chr 1, 7, 16, 19, and X and categorized them based on their most 
likely origin. We explored the potential of increasing average read 
depth using AmpliSeq as a measure to improve variant calling 
and provide evidence that an average read depth of 80–100X, 
which is achievable by loading two samples/PI chip, represents 
an optimal setting.
We did not compare AmpliSeq and SureSelect with WES 
library preparation methods available for the Illumina platform. 
Instead, we especially addressed the scientist using Ion Proton. 
Due to limited resources, we were only able to explore the effect 
of coverage in AmpliSeq but not in SureSelect. We also did not 
explore the regions failed to be sequenced by either library. 
It was, however, already done for AmpliSeq by a recent study 
(Damiati et al., 2016). We did not aim to compare the two library 
preparation methods for CNV analysis at present. The reason 
for our decision is the lack of available tools that allow a direct 
comparison of the two methods for CNV detection. Recently, 
SureSelect Human All Exon V7 became available, which covers 
96% of RefSeq-coding region and could be used on Ion Proton. 
We did not explore the performance of this library preparation 
kit in our protocol. Importantly, our pipeline was optimized for 
hg19 reference assembly. Uplifting hg19 data to GRCh38 led to 
a significant reduction of the target regions for both libraries. 
AmpliSeq HCR decreased from 53.6 to 49.7 MB and SureSelect 
from 54.2 to 50.19 MB. Moreover, we found that the variants in 
the truth set in these target regions also decreased from 48,796 
to 45,749 in AmpliSeq HCR and from 46,557 to 43,453 in 
SureSelect HCR. This is probably due to the fact that both design 
and protocols are optimized for hg19. In case GRCh38 data are 
used, a re-optimization of our protocol is required.
This is the first study evaluating the performance of AmpliSeq 
and the SureSelect, the only two library preparation methods 
available for WES on Ion Proton and is therefore of major 
interest to the users of this technology. Both methods reach high 
validity, but AmpliSeq is faster, requires significantly less input 
material, and outperforms SureSelect in the number of variants 
detected in the RefSeq-coding region. By applying our newly 
developed variant calling pipeline, a further significant increase 
in sensitivity to 95% and PPV to 98% and a dramatic reduction in 
the number of FPs by 90% can be achieved. This improvement is 
highly relevant both in research as well as clinical settings.
DATA AVAILABILITY
The datasets generated and analyzed are available in the Sequence 
Read Archive repository (https://www.ncbi.nlm.nih.gov/sra/
SRP155134).
Exome Sequencing on Ion ProtonGampawar et al.
10 September 2019 | Volume 10 | Article 856Frontiers in Genetics | www.frontiersin.org
ETHICS STATEMENT
The studies involving human participants were reviewed and 
approved by the ethics committee of the Medical University of 
Graz. The patients/participants provided their written informed 
consent to participate in this study.
AUTHOR CONTRIBUTIONS
PG—Sequenced and analyzed the data and wrote the paper. 
YS—Analyzed the data. UW—Collected data and critically read 
the manuscript. BM-M and RS—Critically read the manuscript. 
HS—Study design, obtained the funds, and wrote the paper.
FUNDING
The research reported in this article was funded by the Austrian 
Science Fund grant number P13180, and P20545-B05, by the 
Austrian National Bank Anniversary Fund, P15435, and the 
Austrian Ministry of Science under the aegis of the EU Joint 
Programme—Neurodegenerative Disease Research—www.
jpnd.eu. The project is supported through the following funding 
organizations under the aegis of EU Joint Programme—
Neurodegenerative Disease Research—www.jpnd.eu: Australia, 
National Health and Medical Research Council, Austria, Federal 
Ministry of Science, Research and Economy; Canada, Canadian 
Institutes of Health Research; France, French National Research 
Agency; Germany, Federal Ministry of Education and 
Research; Netherlands, The Netherlands Organisation for 
Health Research and Development; United Kingdom, Medical 
Research Council. This project has received funding from the 
European Union’s Horizon 2020 research and innovation program 
under grant agreement no. 643417. Part of this study was funded 
by the grant Franz Lanyar Stiftung from the Medical University 
of Graz, Austria and by the Austrian Atherosclerosis Society. PhD 
position for PG is supported through the PhD program “Molecular 
Medicine” of Medical University of Graz, Graz, Austria.
ACKNOWLEDGMENTS
We acknowledge the efforts of Johann Semmler-Bruckner for 
sequencing the DNAs. We would like to thank Dr Greg Tyrelle 
from Thermo Fisher Scientific for constant bioinformatics 
support and guidance. The SureSelect All Human Exome V6 
library kit was a present from Agilent technologies.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: 
https://www.frontiersin.org/articles/10.3389/fgene.2019.00856/
full#supplementary-material
REFERENCES
Ardui, S., Ameur, A., Vermeesch, J. R., and Hestand, M. S. (2018). Single molecule 
real-time (SMRT) sequencing comes of age: applications and utilities for 
medical diagnostics. Nucleic Acids Res. 46 (5), 2159–2168. doi: 10.1093/nar/
gky066
Boland, J. F., Chung, C. C., Roberson, D., Mitchell, J., Zhang, X., Im, K. M., et al. 
(2013). The new sequencer on the block: comparison of Life Technology’s 
Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum. 
Genet. 132 (10), 1153–1163. doi: 10.1007/s00439-013-1321-4
Caboche, S., Audebert, C., Lemoine, Y., and Hot, D. (2014). Comparison of 
mapping algorithms used in high-throughput sequencing: application to Ion 
Torrent data. BMC Genomics 15 (1), 264. doi: 10.1186/1471-2164-15-264
Clark, M. J., Chen, R., Lam, H. Y., Karczewski, K. J., Chen, R., Euskirchen, G., et al. 
(2011). Performance comparison of exome DNA sequencing technologies. Nat. 
Biotechnol. 29, 908–914. doi: 10.1038/nbt.1975
Damiati, E., Borsani, G., and Giacopuzzi, E. (2016). Amplicon-based 
semiconductor sequencing of human exomes: performance evaluation 
and optimization strategies. Hum. Genet. 135 (5), 499–511. doi: 10.1007/
s00439-016-1656-8
De Summa, S., Malerba, G., Pinto, R., Mori, A., Mijatovic, V., and Tommasi, S. 
(2017). GATK hard filtering: tunable parameters to improve variant calling for 
next generation sequencing targeted gene panel data. BMC Bioinf. 18 (5), 119. 
doi: 10.1186/s12859-017-1537-8
Ebbert, M. T., Wadsworth, M. E., Staley, L. A., Hoyt, K. L., Pickett, B., Miller, J., 
et al. (2016). Evaluating the necessity of PCR duplicate removal from next-
generation sequencing data and a comparison of approaches. BMC Bioinf. 17 
(7), 491–500. doi: 10.1186/s12859-016-1097-3
Goodwin, S., McPherson, J., and McCombie, W. (2016). Coming of age: ten years 
of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333–351. doi: 
10.1038/nrg.2016.49
Huddleston, J., Chaisson, M. J., Steinberg, K. M., Warren, W., Hoekzema, K., 
Gordon, D., et al. (2017). Discovery and genotyping of structural variation 
from long-read haploid genome sequence data. Genome Res. 27 (5), 677–685. 
doi: 10.1101/gr.214007.116
Kiezun, A., Garimella, K., Do, R., Stitziel, N. O., Neale, B. M., McLaren, P. J., et al. 
(2012). Exome sequencing and the genetic basis of complex traits. Nat. Genet. 
44, 623–630. doi: 10.1038/ng.2303
Lelieveld, S., Spielmannn, M., Mundlos, S., Veltman, J. A., and Gilissen, C. 
(2015). Comparison of Exome and Genome Sequencing Technologies for the 
Complete Capture of Protein-Coding Regions. Hum. Mutat. 2015. 36, 815–822. 
doi: 10.1002/humu.22813
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). 
The sequence alignment/map format and SAMtools. Bioinformatics 25 (16), 
2078–2079. doi: 10.1093/bioinformatics/btp352
Loman, N. J., Misra, R. V., Dallman, T. J., Constantinidou, C., Gharbia, S. E., 
Wain, J., et al. (2012). Performance comparison of benchtop high-
throughput sequencing platforms. Nat. Biotechnol. 30 (5), 434–439. doi: 
10.1038/nbt.2198
Quinlan, A., and Hall, I. (2012). BEDTools: a flexible suite of utilities for comparing 
genomic features. Bioinformatics 26, 841– 42. doi: 10.1093/bioinformatics/
btq033
Robinson, J. T., Thorvaldsdóttir, H., and Winckler, W. (2011). Integrative genomics 
viewer. Nat. Biotechnol. 29, 24–26. doi: 10.1093/bib/bbs017
Samorodnitsky, E., Jewell, B. M., Hagopian, R., Miya, J., Wing, M. R., Lyon, E., et al. 
(2015). Evaluation of hybridization capture versus amplicon-based methods 
for whole-exome sequencing. Hum. Mutat. 36 (9), 903–914. doi: 10.1002/
humu.22825
Schmidt, R., Lechner, H., Fazekas, F., Niederkorn, K., Reinhart, B., Grieshofer, P., 
et al. (1994). Assessment of cerebrovascular risk profiles in healthy persons: 
definition of research goals and the Austrian Stroke Prevention Study (ASPS). 
Neuroepidemiology 13, 308–313. doi: 10.1159/000110396
Seiler, S., Schmidt, H., Lechner, A., Benke, T., Sanin, G., Ransmayr, G., et al. 
(2012). Driving cessation and dementia: results of the prospective registry 
on dementia in Austria (PRODEM). PLoS One 7 (12), e52710. doi: 10.1371/
journal.pone.0052710
Exome Sequencing on Ion ProtonGampawar et al.
11 September 2019 | Volume 10 | Article 856Frontiers in Genetics | www.frontiersin.org
Shigemizu, D., Momozawa, Y., Abe, T., Morizono, T., Boroevich, K. A., 
Takata,  S., et al. (2015). Performance comparison of four commercial 
human whole-exome capture platforms. Sci Rep. 5, 12742. doi: 10.1038/
srep12742
Subramanian, S., Mishra, R. K., and Singh, L. (2003). Genome-wide analysis of 
microsatellite repeats in humans: their abundance and density in specific 
genomic regions. Genome Biol. 4 (2), R13. doi: 10.1186/gb-2003-4-2-r13
Tan, A., Abecasis, G., and Kang, H. (2015). Unified representation of genetic 
variants. Bioinformatics 31, 2202–2204. doi: 10.1093/bioinformatics/
btv112
van Dijk, E., Auger, H., Jaszczyszyn, Y., and Thermes, C. (2014). Ten years of 
next-generation sequencing technology. Trends Genet. 30, 418–426. doi: 
10.1016/j tig.2014.07.001
Vanni, I., Coco, S., Truini, A., Rusmini, M., Dal Bello, M., Alama, A., et al. (2015). 
Next-generation sequencing workflow for NSCLC critical samples using a 
targeted sequencing approach by Ion Torrent PGM™ platform. Int. J. Mol. Sci. 
16 (12), 28765–28782. doi: 10.3390/ijms161226129
Zook, J. M., Catoe, D., McDaniel, J., Vang, L., Spies, N., Sidow, A., et al. (2016). 
Extensive sequencing of seven human genomes to characterize benchmark 
reference materials. Sci. Data 3, 160025. doi: 10.1038/sdata.2016.25
Zook, J. M., Chapman, B., Wang, J., Mittelman, D., Hofmann, O., Hide, W., et al. 
(2014). Integrating human sequence data sets provides a resource of benchmark 
SNP and indel genotype calls. Nat. Biotechnol. 32, 246–251. doi: 10.1038/nbt.2835
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2019 Gampawar, Saba, Werner, Schmidt, Müller-Myhsok and Schmidt. This 
is an open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) and the copyright owner(s) are credited and that the 
original publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these terms.
